secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001171843-23-006678
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q3 revenue $41.5M (+3% YoY); raises FY2023 guidance to $164-166M
----------------------------------------------------------------------

- Revenue $41.5M (+3% YoY); Joint Preservation & Restoration up 14% to $13.5M, OA Pain Mgmt up 2% to $24.9M.
- Net loss ($6.6M), ($0.45)/share; adjusted net income $0.00/diluted share; includes $4.2M software charge.
- Adjusted EBITDA $4.7M vs $4.1M; cash from ops $6.5M, cash $70.7M.
- Raised FY2023 revenue guidance to $164-166M (from $159.5-163M), implying 5-6% growth.
- FDA cleared Integrity Implant System (rotator cuff patch) and X-Twist biocomposite; launches Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184323006678/0001171843-23-006678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184323006678/f8k_110223.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer